Educational information on regenerative approaches being studied for the cellular and inflammatory processes involved in metabolic disease. Investigational and not FDA-approved.
Metabolic disease covers a wide range of conditions, from insulin resistance and prediabetes to type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD). These conditions share a common root cause: the gradual breakdown of how cells produce and use energy. This is often made worse by excess body fat, gut dysfunction, and inactivity. Together, they make up the most common chronic disease burden in the modern world.
Chronic systemic inflammation is the common thread across all of these conditions. People with metabolic disease have elevated levels of inflammatory molecules in their blood. These molecules block the body's response to insulin, damage blood vessel walls, and accelerate organ damage over time. Managing blood sugar alone does not resolve this inflammation. If the root biology is not addressed, the problem keeps getting worse.
Conventional treatments do a good job managing symptoms like blood glucose, blood pressure, and cholesterol. They focus on managing these symptoms rather than the underlying inflammation or cellular energy problems. Regenerative medicine is being studied for its potential effects on these root causes. Researchers are exploring whether cell signals might influence inflammation and cellular function, but these effects are not proven, results vary, and these therapies are not FDA-approved for metabolic disease.
Our protocols are designed to support patients across the metabolic disease spectrum. Each approach is based on the latest evidence for each condition.
Type 2 diabetes involves progressive insulin resistance and stress on the cells that produce insulin. Over time, it can cause serious complications throughout the body. Researchers are studying whether MSC-based approaches might influence inflammation and metabolic markers, but these effects are not established, and this use is investigational and not FDA-approved.
Metabolic syndrome is a cluster of cardiovascular risk factors including belly fat, abnormal cholesterol, high blood pressure, and elevated blood sugar. It reflects widespread inflammation in fat tissue and blood vessels. Researchers are studying whether regenerative protocols might influence this inflammation; benefits are not established and results vary.
Non-alcoholic fatty liver disease is driven by liver inflammation, fat buildup, and progressive scarring. Early research is exploring whether MSC-derived signals might affect liver inflammation, but results are preliminary, benefits are not established, and this use is investigational.
Persistent fatigue in people with metabolic disease is often rooted in poor cellular energy production and ongoing inflammation, not just lifestyle factors. Researchers are studying whether exosome-based approaches might influence cellular energy and inflammation; these effects are not proven and individual results vary.
Each protocol is built around your lab results and tailored to your specific health profile.
Before any plan is designed, the treating physician runs a full baseline evaluation including blood sugar markers, insulin levels, inflammation markers, lipid panel, and liver function tests. This clinical evaluation is performed by the provider, not by GSS.
Based on your labs and health history, the treating provider builds an IV MSC or exosome protocol tailored to your metabolic profile, organ function, and goals. The treating provider determines the right dose, cell source, and session schedule at this stage.
Treatment is given by intravenous infusion in an outpatient setting, typically over one to three sessions spaced four to eight weeks apart. The procedure is well-tolerated and does not require hospitalization or extended recovery.
The treating physician runs repeat lab panels after treatment to assess your metabolic response and any changes in inflammation and blood sugar markers. This clinical follow-up is conducted by the provider, not by GSS. Ongoing communication with our coordination team supports continuity of care.
Not sure whether this applies to your case? Candidacy is determined by medical review of your history and imaging, not by a form. The consultation is complimentary.
See If You QualifyMetabolic improvement happens gradually. The following is a general framework. Individual results vary based on your starting health, how closely you follow the protocol, and lifestyle factors.
Systemic inflammation begins to settle. Some patients notice improved energy and less persistent fatigue as the initial anti-inflammatory response kicks in.
Any changes in metabolic markers are assessed by the treating physician. Individual responses vary and no specific outcome is guaranteed.
Any changes in blood sugar or metabolic lab results are assessed by the treating physician. Individual responses vary and no specific outcome is guaranteed.
Metabolic markers continue to improve. Most benefit is realized and maintained with appropriate lifestyle management and ongoing clinical monitoring.
Regenerative metabolic protocols are designed for a specific patient profile. The following criteria guide our evaluation process.
Research has examined type 2 diabetes, metabolic syndrome and chronic inflammatory conditions. These remain areas of study rather than established treatment.
No. Nothing here replaces prescribed medication, and stopping or altering treatment without your prescribing physician is dangerous. Any regenerative approach would be discussed alongside your existing care, not instead of it.
Many chronic metabolic conditions involve persistent low-grade inflammation. Mesenchymal stem cells are studied partly for their apparent influence on inflammatory signalling, though whether that produces clinical benefit in these conditions is not established.
No. These are investigational therapies, not approved by the U.S. Food and Drug Administration for metabolic or chronic inflammatory disease. Procedures take place in Mexico under COFEPRIS regulation, which is a separate framework from FDA approval.
A physician reviews your diagnosis, laboratory results, current medications, and how well your condition is presently controlled. Uncontrolled disease frequently rules out candidacy.
Connect with our coordination team to explore whether regenerative therapy may be available for your metabolic condition and goals through an independent provider.
CHECK IF YOU QUALIFY →Medically reviewed by Dr. Karla Chavira, MD, Regenerative Medicine Physician and CEO of CMCells (Cédula Profesional on file).
Last reviewed: July 2026